Risk of Gadolinium-Based Contrast Agents in Chronic Kidney Disease—Is Zero Good Enough?

Author:

Maripuri Saugar12,Johansen Kirsten L.12

Affiliation:

1. Division of Nephrology, Department of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota

2. Department of Medicine, University of Minnesota, Minneapolis

Publisher

American Medical Association (AMA)

Subject

Internal Medicine

Reference8 articles.

1. Gadolinium-based contrast agents: a comprehensive risk assessment.;Fraum;J Magn Reson Imaging,2017

2. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.;Marckmann;J Am Soc Nephrol,2006

3. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?;Grobner;Nephrol Dial Transplant,2006

4. Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent: a systematic review and meta-analysis;Woolen;JAMA Intern Med

5. US Food and Drug Administration. Public health advisory—gadolinium containing contrast agents for magnetic resonance imaging (MRI). http://wayback.archive-it.org/7993/20170112033022/http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm053112.htm. Published June 8, 2006. Accessed September 19, 2019.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3